Label Expansion for Roche's Avastin - Analyst Blog

By
A A A

The US Food and Drug Administration (FDA) recently approved Roche 's ( RHHBY ) Avastin (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for treating patients suffering from metastatic colorectal cancer (mCRC).

Patients suffering from mCRC and initially treated with Avastin along with an irinotecan or oxaliplatin containing chemotherapy may now continue to receive Avastin plus a different irinotecan or oxaliplatin containing chemotherapy if the cancer worsens (second-line treatment).

We note that the FDA's approval was based on encouraging results from a phase III study (ML18147). Results from the study showed that patients continuing with an Avastin-based regimen, even after the worsening of their cancer, survived longer than those who underwent chemotherapy alone. The risk of death for patients who received Avastin plus standard chemotherapy as both the first- and second-line treatment of mCRC, was 19% lower in comparison to patients receiving chemotherapy alone.


Notably, this is Roche's third approval for Avastin as a treatment of mCRC. The drug is already approved by the FDA for treating patients suffering from mCRC in combination with intravenous 5FU-based chemotherapy. Roche has also gained approval for Avastin for treating patients whose cancer worsened after chemotherapy alone.

Avastin plus fluoropyrimidine-based chemotherapy is approved in the EU for the treatment of adults suffering from metastatic carcinoma of the colon or rectum.

We are pleased with Avastin's label expansion. The mCRC market boasts of big players like Bristol-Myers Squibb Company ( BMY ).

Roche carries a Zacks Rank #3 (Hold). However, other large cap pharma stocks such as Bayer ( BAYRY ) and Eli Lilly and Company ( LLY ) carry a Zacks Rank #2 (Buy).



BAYER A G -ADR (BAYRY): Free Stock Analysis Report

BRISTOL-MYERS (BMY): Free Stock Analysis Report

LILLY ELI & CO (LLY): Free Stock Analysis Report

(RHHBY): ETF Research Reports

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: BAYRY , BMY , LLY , RHHBY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

33,110,376
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
24,486,872
  • $7.41 ▲ 2.07%
20,864,535
  • $7.39 ▼ 2.76%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com